Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.
Furl R, Scarsi KK, Sayles H, Anderson M, Ofimboudem JD, Weld ED, Waked I, Gomaa A, Al-Khatib A, Elshobary FM, Desalegn H, Fisseha H, Solomon S, Mehta S, Owen A, Rannard S, Thomas DL, Swindells S. Furl R, et al. Among authors: desalegn h. J Viral Hepat. 2024 Nov 15. doi: 10.1111/jvh.14031. Online ahead of print. J Viral Hepat. 2024. PMID: 39545599
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.
Cao Z, Wong F, Choudhury AK, Kamath PS, Topazian M, Torre A, Hayes PC, George J, Idilman R, Seto WK, Desalegn H, Alvares-da-Silva MR, Bush BJ, Thacker LR, Xie Q, Bajaj JS; CLEARED Consortium. Cao Z, et al. Among authors: desalegn h. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):997-1009. doi: 10.1016/S2468-1253(24)00224-3. Epub 2024 Sep 5. Lancet Gastroenterol Hepatol. 2024. PMID: 39243795
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B.
Johannessen A, Reikvam DH, Aleman S, Berhe N, Weis N, Desalegn H, Stenstad T, Heggelund L, Samuelsen E, Karlsen LN, Lindahl K, Pettersen FO, Iversen J, Kleppa E, Bollerup S, Winckelmann AA, Brugger-Synnes P, Simonsen HE, Svendsen J, Kran AB, Holmberg M, Olsen IC, Rueegg CS, Dalgard O. Johannessen A, et al. Among authors: desalegn h. Aliment Pharmacol Ther. 2024 Aug;60(4):434-445. doi: 10.1111/apt.18147. Epub 2024 Jul 5. Aliment Pharmacol Ther. 2024. PMID: 38970293 Clinical Trial.
Hepatitis B discrimination: global responses requiring global data.
Freeland C, Qureshi A, Wallace J, Kabagambe K, Desalegn H, Munoz C, Lee D, Owusu-Ansah T, Adda D, Ndow G, Yousif S, Abdalla H, Kheir O, Tu T, Cohen C. Freeland C, et al. Among authors: desalegn h. BMC Public Health. 2024 Jun 11;24(1):1575. doi: 10.1186/s12889-024-18918-8. BMC Public Health. 2024. PMID: 38862929 Free PMC article.
Impact of alcohol use on liver disease outcomes.
Desalegn H, Diaz LA, Rehm J, Arab JP. Desalegn H, et al. Clin Liver Dis (Hoboken). 2024 Jun 7;23(1):e0192. doi: 10.1097/CLD.0000000000000192. eCollection 2024 Jan-Jun. Clin Liver Dis (Hoboken). 2024. PMID: 38860129 Free PMC article. Review.
Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.
Gupta N, Swindells S, Scarsi KK, Furl R, Thomas DL, Weld ED, Ofimboudem JD, Desalegn H, Hamid S, Rosas AT, Miranda AE, Owen A, Rannard S, Hiebert L, Sun K, Ward JW. Gupta N, et al. Among authors: desalegn h. J Viral Hepat. 2024 May;31(5):221-232. doi: 10.1111/jvh.13921. Epub 2024 Mar 28. J Viral Hepat. 2024. PMID: 38545826
Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.
Minier N, Guingané AN, Okeke E, Sinkala E, Johannessen A, Andersson MI, Davwar P, Desalegn H, Duguru M, Fall F, Mboup S, Maponga T, Matthews PC, Ramírez Mena A, Ndow G, Orlien SMS, Riches N, Seydi M, Sonderup M, Spearman CW, Stockdale AJ, Taljaard J, Vinikoor M, Wandeler G, Lemoine M, Shimakawa Y, Sombié R. Minier N, et al. Among authors: desalegn h. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):323-332. doi: 10.1016/S2468-1253(23)00449-1. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367633 Free PMC article.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
72 results